BioAge Labs, Inc. - Common Stock (NQ:BIOA)

7.890 +0.140 (+1.81%)

Streaming Delayed Price Updated: 9:41 AM EDT, Sep 17, 2026 Add to My Watchlist

Price and Volume

Volume	24,616
Open	7.850
Bid (Size)	7.830 (200)
Ask (Size)	7.900 (200)
Prev. Close	7.750
Today's Range	7.850 - 8.000
52wk Range	4.680 - 25.95
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema

September 08, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Upcoming Investor Conferences

September 02, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Performance

YTD	-38.5%	-38.5%
1 Month	-24.1%	-24.1%
3 Month	-60.5%	-60.5%
6 Month	-59.2%	-59.2%
1 Year	+61.0%	+61.0%

More News

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 05, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Top movers in Friday's session ↗

July 31, 2026

Via Chartmill

Top stock movements in today's session. ↗

July 31, 2026

Via Chartmill

Gapping stocks in Friday's session ↗

July 31, 2026

Via Chartmill

Friday's pre-market session: top gainers and losers ↗

July 31, 2026

Via Chartmill

BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk

June 16, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease ↗

June 06, 2026

Via MarketBeat

BioAge Labs to Present at Upcoming Investor Conferences

May 22, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

May 20, 2026

Via FinancialNewsMedia

A Healthcare Fund Just Made Bitgo Its Biggest Bet ↗

May 19, 2026

Via The Motley Fool

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗

May 08, 2026

Via MarketBeat

BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates

May 08, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026

May 04, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP

April 21, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference

April 13, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025

March 24, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Pricing of Upsized $115.0 Million Public Offering

January 21, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Proposed Public Offering

January 20, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

January 20, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk

January 12, 2026

From BioAge Labs, Inc.

Via GlobeNewswire

Tuesday's after hours session: top gainers and losers ↗

January 06, 2026

Via Chartmill

2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole ↗

December 13, 2025

Via The Motley Fool

Frequently Asked Questions

Is BioAge Labs, Inc. - Common Stock publicly traded?

Yes, BioAge Labs, Inc. - Common Stock is publicly traded.

What exchange does BioAge Labs, Inc. - Common Stock trade on?

BioAge Labs, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioAge Labs, Inc. - Common Stock?

The ticker symbol for BioAge Labs, Inc. - Common Stock is BIOA on the Nasdaq Stock Market

What is the current price of BioAge Labs, Inc. - Common Stock?

The current price of BioAge Labs, Inc. - Common Stock is 7.890

When was BioAge Labs, Inc. - Common Stock last traded?

The last trade of BioAge Labs, Inc. - Common Stock was at 09/17/26 09:41 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.